Division of Endocrinology, Diabetes, and Metabolism, Mount Sinai Diabetes Center, and T1D Clinical Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Emory University School of Medicine, Atlanta, GA, USA.
J Diabetes Sci Technol. 2024 Sep;18(5):1198-1207. doi: 10.1177/19322968231161317. Epub 2023 Mar 15.
Gestational diabetes mellitus (GDM) is a common metabolic disease of pregnancy that threatens the health of several million women and their offspring. The highest prevalence of GDM is seen in women of low socioeconomic status. Women with GDM are at increased risk of adverse maternal outcomes, including increased rates of Cesarean section delivery, preeclampsia, perineal tears, and postpartum hemorrhage. However, of even greater concern is the increased risk to the fetus and long-term health of the child due to elevated glycemia during pregnancy. Although the use of continuous glucose monitoring (CGM) has been shown to reduce the incidence of maternal and fetal complications in pregnant women with type 1 diabetes and type 2 diabetes, most state Medicaid programs do not cover CGM for women with GDM. This article reviews current statistics relevant to the incidence and costs of GDM among Medicaid beneficiaries, summarizes key findings from pregnancy studies using CGM, and presents a rationale for expanding and standardizing CGM coverage for GDM within state Medicaid populations.
妊娠期糖尿病(GDM)是一种常见的妊娠代谢疾病,威胁着数百万女性及其后代的健康。GDM 的最高患病率出现在社会经济地位较低的女性中。患有 GDM 的女性发生不良母婴结局的风险增加,包括剖宫产率增加、子痫前期、会阴裂伤和产后出血。然而,更令人担忧的是,由于怀孕期间血糖升高,胎儿和儿童的长期健康风险增加。尽管连续血糖监测(CGM)的使用已被证明可降低 1 型和 2 型糖尿病孕妇的母婴并发症发生率,但大多数州的医疗补助计划并不涵盖 GDM 女性的 CGM。本文回顾了与医疗补助受益人群中 GDM 的发生率和成本相关的当前统计数据,总结了使用 CGM 的妊娠研究的关键发现,并提出了在州医疗补助人群中扩大和标准化 GDM 覆盖范围的理由。